COMPANY

Prolynx, LLC

HQ: Emeryville, CA source · prolynxinc.com ↗ · West Coast

Location: Emeryville, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: hypoparathyroidism PLX038

Timeline

Dec 11, 2025 Raise Private equity round — Series A: $70M (total, as published), announced Dec 11, 2025. Source: company release on GlobeNewswire. source ↗
2016-03 Trial start I: A Phase I Study of PLX038 in Patients With Advanced Solid Tumors source ↗

Raised: $70.0M. Last 2 years.

Dec 11, 2025 Private equity round — Series A: $70M (total, as published), announced Dec 11, 2025. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT02646852	A Phase I Study of PLX038 in Patients With Advanced Solid Tumors	I	Completed	2016-03	2023-02 (actual)

Annual award amounts. Total $689K.

Jun 22, 2020 NIH award 1R43DK125144-01 FY2020: $245,871 awarded for that fiscal year; activity R43 (SBIR); PI SCHNEIDER, ERIC L; recipient as written: PROLYNX, LLC, SAN FRANCISCO, CA. A long acting parathyroid hormone (PTH) 1-34 source ↗
Sep 19, 2017 NIH award 1R43DK116347-01 FY2017: $149,575 awarded for that fiscal year; activity R43 (SBIR); PI ASHLEY, GARY W; recipient as written: PROLYNX, LLC, SAN FRANCISCO, CA. A facile approach for preparing dual-agonists wi source ↗
Jul 9, 2010 NIH award 1R43DK089805-01 FY2010: $149,650 awarded for that fiscal year; activity R43 (SBIR); PI SANTI, DANIEL V; recipient as written: PROLYNX, LLC, SAN FRANCISCO, CA. Releasable attachment of drugs to PEGylated den source ↗
May 21, 2010 NIH award 1R43DK088481-01 FY2010: $143,958 awarded for that fiscal year; activity R43 (SBIR); PI ASHLEY, GARY W; recipient as written: PROLYNX, LLC, SAN FRANCISCO, CA. Releasable site-specific attachment of macromole source ↗

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗